Oncimmune Holdings (ONC ) has signed a new partnership with Synexa Life Sciences BV whereby its clients will utilise the autoantibody services of the ImmunoINSIGHTS platform.
Synexa Life Sciences BV, a biotechnology company that is focused on delivering a range of biomarker analytical and advisory services in translational and clinical research, selected Oncimmune’s ImmunoINSIGHTS platform following a competence and capability assessment.
This ‘go-to-market’ collaborative partnership is expected to allow for comprehensive characterisation of the B-cell immune response in disease and treatment indications.
Both Oncimmune Holdings and Synexa Life Sciences BV are similar in the way they utilise technologies to identify biological signatures, ‘leveraging their expertise in the immunological underpinnings of health and disease to improve patient diagnostics and therapeutics.’
Under the terms of the agreement and over the next 18 months, Synexa Life Sciences plans to sign multiple new contracts with their partners for autoantibody profiling acting to broaden and enhance ImmunoINSIGHT’s own business development efforts, the company outlined.
Oncimmune says this new strategic collaboration comes at a time when autoantibody profiling, which provides a depth and breadth of clinical data to improve response and adverse event (irAE) prediction, patient screening and diagnostic accuracy, ‘is experiencing substantial interest, with the market segment growing at approximately 27% year-upon-year.’
Commenting, Dr Adam M Hill, CEO of Oncimmune Holding said: “The ImmunoINSIGHTS team look forward to the opportunity to deliver high quality, value-adding analysis and interpretation of blood samples for Synexa and its clients, delivering a differentiated service to customers that are yet to engage with our proprietary technology platform.”
On Monday, the immunodiagnostics group announced that it had signed a commercial collaboration deal with a healthcare company owned by Google’s parent, Alphabet.
The contract will focus on the autoantibody profiling of patients who have had the COVID-19 infection and have gone on to develop long lasting symptoms lasting more than four weeks.
Oncimmune said it will utilise its recently validated infectious disease panel of biomarkers to evaluate whether autoantibodies are associated with the development of “Long COVID”.
The Company’s infectious disease panel will also be used to assess whether these autoantibodies remain elevated in long COVID patients during their period of recovery.
Should this initial discovery phase prove successful, both Oncimmune and Verily have retained the rights to commercialise the resultant intellectual property, including the filing of patent applications for the development of a companion diagnostic, the company noted.
Meanwhile, in a separate statement, Oncimmune said it expects its ImmunoINSIGHTS to become a leading player in the autoantibody profiling segment of pharma services by FY23.
In its half-year results for period to 30 November 2021, the group, which highlighted a solid ImmunoINSIGHTS pipeline, said this growth will be supported by an “enviable list” of existing blue-chip customers, which includes “many of the world’s leading pharmaceutical companies.”
Since launching the ImmunoINSIGHTS business back in 2020, the company has secured contracts with five of the top ten global pharma companies. This is expected to constitute around 70% of revenue for FY22. The Group added that most of these clients have multiple studies, with five separate programmes underway with the world’s leading oncology group.
The number of contracted clients has more than doubled from FY21 to 13, with three of these currently running multiple contracts each. The company said momentum has continued to accelerate post period, particularly in terms of number of orders and its forecast pipeline.
In particular, the company highlighted to investors that there is increasing visibility from project extensions as well as additional contracts in other areas for Oncimmune’s existing clients.
The company currently anticipates that by the end of FY22 approximately 70% of FY22 group revenues will have been earned from contracts with the top ten pharmaceutical companies.
Follow News & Updates from Oncimmune Holdings: